Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Assets Average data on record, last reported at $579.7 million in Q3 2025.

  • For Q3 2025, Assets Average fell 14.59% year-over-year to $579.7 million; the TTM value through Sep 2025 reached $579.7 million, down 14.59%, while the annual FY2024 figure was $616.4 million, 33.2% up from the prior year.
  • Assets Average reached $579.7 million in Q3 2025 per VRDN's latest filing, down from $757.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $757.2 million in Q4 2024 and bottomed at $120.5 million in Q2 2021.
  • Average Assets Average over 5 years is $379.8 million, with a median of $369.1 million recorded in 2023.
  • Peak YoY movement for Assets Average: skyrocketed 411.79% in 2021, then dropped 14.59% in 2025.
  • A 5-year view of Assets Average shows it stood at $212.5 million in 2021, then surged by 106.08% to $437.8 million in 2022, then fell by 6.45% to $409.6 million in 2023, then surged by 84.86% to $757.2 million in 2024, then fell by 23.43% to $579.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $579.7 million in Q3 2025, $757.2 million in Q4 2024, and $678.8 million in Q3 2024.